• Blog
  • Transforming Growth Factor Beta 1 Market Report

    Transforming Growth Factor Beta 1 Market Report

    Transforming Growth Factor Beta 1 Market Report
    Report code - SRHL239 Delivery - 2 Weeks
    Get Free Sample |
    Play Audio
    Listen
    Global Transforming Growth Factor-Beta 1 Market, Dynamics, and Market Analysis
    See more...

    Impact of COVID-19 on Transforming Growth Factor Beta 1 Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on Transforming Growth Factor Beta 1 Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Insights

    The Global Transforming Growth Factor-Beta 1 Market is expected to grow from USD 1.1 billion in 2020 to USD 2.0 billion by 2026 at a CAGR of over 11.1% during the forecast period.

    Figure: Global Transforming Growth Factor-Beta 1 Market Size, 2020-2026 (USD Billion)

    Transforming-Growth-Factor-Beta-1-Market-Forecast

    Wish to get a sample report? Click here

    What is Transforming growth factor beta 1?

    Transforming growth factor-beta 1 is a multifunctional regulatory polypeptide member of the growth factor-beta family of cytokines. It is defined as a protein that performs various cellular functions including cell differentiation, cell growth, cell proliferation, and apoptosis. It also plays an important role in pathologic processes.

    Key Players

    Key players operating in the global Transforming Growth Factor-Beta 1 Market are-

    • F. Hoffmann-La Roche AG (Switzerland),
    • Shionogi & Company, Limited (Japan),
    • Isarna Holding GmbH (Germany),
    • Scholar Rock Holding (The U.S),
    • Acceleron Pharma, Inc. (The U.S),
    • Sanofi Genzyme (The U.S),
    • Sirnaomics, Inc. (The U.S),
    • Eli Lilly and Company (The U.S),
    • Novartis International AG (Switzerland), and
    • Formation Biologics Inc. (The U.S).

    Market Dynamics

    The growth of the global transforming growth factor-beta 1 market is primarily driven by its increasing usage in treating diseases such as cancer and idiopathic pulmonary fibrosis.

    • It inhibits primary tumor development and growth by inducing cell cycle arrest and apoptosis.
    • An increasing number of people suffering from various cancers is likely to drive the growth of the transforming growth factor-beta 1 market at a significant rate during the review period.
    • Growing emphasis on investment in R&D activities is likely to create lucrative opportunities for the players operating in the global market.

    Segment Analysis

    Application Trends

    Based on application, the market has been segmented into idiopathic pulmonary fibrosis (IPF), cancer, and others. Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal lung disease. The idiopathic pulmonary fibrosis segment accounted for the largest market share in 2020. The cancer segment is projected to register a higher CAGR during the review period on account of the increasing prevalence of cancer among people.

    Regional Trends

    Geographically, the market in Europe accounted for the largest market share in 2020 and is expected to grow at a steady rate during the review period.

    • The market growth can be attributed to presence of strong healthcare industry and continuous investment in R&D activities to develop advanced solutions for the healthcare problems.
    • The market in Asia-Pacific region is expected to increase at a significant rate on account of growing healthcare industry with increasing prevalence of diseases among consumers.

    COVID-19 Impact on Global Transforming Growth Factor Beta 1 Market

    The outbreak of covid-19 across regions led to the imposition of lockdown across geographies, border restrictions, and the breakdown of the transportation network. This resulted in the closure of factories which break affected the market growth. The ongoing treatment of the patients with cancer and IPF diseases was not affected due to the covid-19 outbreak as people were allowed to go out for medical emergencies.

    Critical Questions Answered in the Report

    • What are the key trends in the global transforming growth factor beta 1 market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on global transforming growth factor beta 1 market?
    • What are the key strategies adopted by the major vendors to lead in the global transforming growth factor-beta 1 market?
    • What is the market share of the top vendors?

    Want to know the full scope of the report? Register Here

    Target Audience

    Here is the list of the group of customers that the Global transforming growth factor-Beta 1 market hopes to have the greatest opportunity to convert-

    • Transforming growth factor beta 1 manufacturers
    • Transforming growth factor beta 1 suppliers
    • Transforming growth factor beta 1 distributors
    • Organizations
    • Government bodies

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].

    Frequently Asked Questions (FAQs)

    The transforming growth factor beta 1 market size is expected to reach USD 2.0 billion in the foreseeable future.

    F. Hoffmann-La Roche AG (Switzerland), Shionogi & Company, Limited (Japan), Isarna Holding GmbH (Germany), Scholar Rock Holding (The U.S), Acceleron Pharma, Inc. (The U.S), Sanofi Genzyme (The U.S), Sirnaomics, Inc. (The U.S), Eli Lilly and Company (The U.S), Novartis International AG (Switzerland) and Formation Biologics Inc. (The U.S) are among the key players in the transforming growth factor beta 1 market.

    The transforming growth factor beta 1 market is expected to witness an impressive growth of 11.1% CAGR in the coming years.

    Europe accounted for the largest share of transforming growth factor beta 1 market in 2020.

    The idiopathic pulmonary fibrosis segment is expected to register higher CAGR in the transforming growth factor beta 1 market in the coming years.

    Increasing usage in treating diseases such as cancer and idiopathic pulmonary fibrosis, increasing number of people suffering from various cancers, Growing emphasis on investment in R&D activities are the factors driving the growth of transforming growth factor beta 1 market.

    Transforming growth factor beta 1 manufacturers, Transforming growth factor beta 1 suppliers, Transforming growth factor beta 1 distributors, Organizations, Government bodies are the target audience in the transforming growth factor beta 1 market.

    •